维思通治疗首发精神分裂症临床观察

Clinical Observation of Risperidone in the Treatment of First-episode Schizophrenics

为观察维思通对首发精神分裂症的疗效,对符合CCMD-2-R精神分裂症诊断的首发病人,接受维思通治疗,并于治疗前及治疗后1、2、4、8周使用简明精神病量表(BPRS)及副反应量表(TESS)评定。结果,维思通对于首发精神分裂症各种类型均有较好疗效,不良反应以静坐不能、口干、便秘、心动过速较常见。提示,维思通对于首发精神分裂症有较好的疗效。

In rder to observe the therapeutic effect of risperidone in the treatment of first-episode schizophrenics, the patients who were diagnosed according to CCMD-2-R were given risperidone for 8 weeks,and the curative effect and side effect were evaluated with BPRS and TESS at pre-treatment, and in the 1st, 2nd , 4thand 8thweeks of treatment. Results:There was better therapeutic effect of risperidone in the treatment of all types of first-episode schizophrenics, the adverse reactions were akathisia, xerostomia, constipation and tachycardia. Conclusion: Risperdone had better therapeutic effect on first-episode schizophrenia.